Evidence map›Paper›PMID 41504311›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Endothelial Cell-Based Vascular Bandages for Blood-Brain Barrier Repair and Targeted siRNA Delivery.

Yaosheng Li, Yunfei Dong, Yaode He, Juanjuan Zheng, Hui Liu, Lu Li, Xiaoxu Hao, Yanli Zhao, Zefeng Yang, Yuankai Sun and 14 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Yaosheng LiState Key Laboratory of Advanced Drug Delivery and Release Systems, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang, P. R. China.
Yunfei DongState Key Laboratory of Advanced Drug Delivery and Release Systems, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang, P. R. China.
Yaode HeDepartment of Neurology, The Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, Zhejiang, P. R. China.
Juanjuan ZhengState Key Laboratory of Advanced Drug Delivery and Release Systems, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang, P. R. China.
Hui LiuState Key Laboratory of Advanced Drug Delivery and Release Systems, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang, P. R. China.
Lu LiState Key Laboratory of Advanced Drug Delivery and Release Systems, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang, P. R. China.
Xiaoxu HaoLingang Laboratory, Shanghai, P. R. China.
Yanli ZhaoLingang Laboratory, Shanghai, P. R. China.
Zefeng YangState Key Laboratory of Advanced Drug Delivery and Release Systems, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang, P. R. China.
Yuankai SunState Key Laboratory of Advanced Drug Delivery and Release Systems, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang, P. R. China.
Zhiwei DuState Key Laboratory of Advanced Drug Delivery and Release Systems, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang, P. R. China.
Bo ZhaoDepartment of Pharmacy, Ningbo Municipal Hospital of Traditional Chinese Medicine (TCM), Affiliated Hospital of Zhejiang Chinese Medical University, Ningbo, Zhejiang, P. R. China.
Weihang ZhouState Key Laboratory of Advanced Drug Delivery and Release Systems, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang, P. R. China.
Honghui WuJinhua Institute of Zhejiang University, Jinhua, Zhejiang, P. R. China.
Tianyuan ZhangState Key Laboratory of Advanced Drug Delivery and Release Systems, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang, P. R. China.
Jiahe WuKey Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Department of Pharmacy, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, Zhejiang, P. R. China.
Xiangrui LiuInnovation Center of Yangtze River Delta, Zhejiang University, Jiaxing, Zhejiang, P. R. China.
Xianzhen YinLingang Laboratory, Shanghai, P. R. China.
Zhicai ChenDepartment of Neurology, The Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, Zhejiang, P. R. China.
Rui XueDepartment of Neurology, The Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, Zhejiang, P. R. China.
Min LouDepartment of Neurology, The Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, Zhejiang, P. R. China.
Zhen GuState Key Laboratory of Advanced Drug Delivery and Release Systems, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang, P. R. China.
Xinchi JiangState Key Laboratory of Advanced Drug Delivery and Release Systems, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang, P. R. China.
Jianqing GaoState Key Laboratory of Advanced Drug Delivery and Release Systems, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang, P. R. China.ORCID https://orcid.org/0000-0003-1052-7060

Funding

Dr. Li Dak Sum & Yip Yio chin Development Fund for Regenerative Medicine, Zhejiang UniversityNational Natural Science Foundation of China 82003668National Natural Science Foundation of China U22A20383Natural Science Foundation of Zhejiang Province LD22H300002Natural Science Foundation of Zhejiang Province LQ21H300002Ningbo Top Medical and Health Research Program 2022030107Shanghai Excellent Academic Leader (Youth) 23XD1460400)
6 · The paper itself

Abstract

Changes in the blood-brain barrier (BBB) are key targets for mitigating cerebral ischemia/reperfusion injury. The rapid progression of reperfusion injury necessitates the development of carriers that target and regulate early BBB disruption, while supporting its structure and function during BBB recovery. This study proposes the use of brain microvascular endothelial cell (mECs)-based vascular bandages carrying siRNAs to simultaneously target, support, and regulate the damaged BBB. Specifically, mECs can target damaged cerebral blood vessels after intravenous injection by interacting with the highly expressed very late antigen - 4 (VLA-4) in the vessels. Furthermore, by covering the cerebral blood vessels and forming new junction proteins with the vascular endothelium, mECs support the permeability and structural integrity of the vasculature. Additionally, oxygen-glucose deprivation-treated mEC culture supernatants (OGD-SN) can promote connexin 43 (CX43) expression, facilitating the delivery of therapeutic p66

Indexed as

Blood-Brain BarrierBrain IschemiaEndothelial CellsReperfusion InjuryRNA, Small InterferingAnimalsDisease Models, AnimalMaleRNA, Small InterferingBBBbiomaterialsendothelial cellsischemic/reperfusion injurynucleic acid drugstargeting drug delivery systems

Identifiers

PMID41504311
PMCPMC12955897

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.